Andrea Biondo

Fulham Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 24, 2025

Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.

Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.

Journal: Cancer research communications

Published: September 25, 2023

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 06, 2022

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.

Journal: Journal of immunotherapy and precision oncology

Published: April 23, 2021

Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.

Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.

Journal: Cancer treatment and research communications

Published: December 03, 2020

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 21, 2016

Pazopanib-induced alopecia, an underestimated toxicity?

Pazopanib-induced alopecia, an underestimated toxicity?

Journal: Frontiers in oncology

Published: February 05, 2015

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 21, 2014

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Journal: Journal of hematology & oncology

Published: September 26, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026